Day

November 2, 2012
Watson Pharmaceuticals has completed its 4.25 billion Euro acquisition of Swiss competitor Actavis Group, making Watson the third-largest generic drug company worldwide. BDK advised Watson on their acquisition of Actavis’...
Read More

ARCHIVE